PharmaShots Weekly Snapshot (November 04-08, 2019)
?1. Triumviras TAC01-CD19 Receives FDAs Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma
Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell Lymphoma
Published: Nov 07, 2019 | Tags: Janssen, Reports, Submission, MAA, EMA, Ebola Vaccine Regimen, Prevent, Ebola Virus Disease
Published: Nov 07, 2019 | Tags: Yuhan Pharmaceutical, Collaborates, Cyclica, Enhance, Drug Development, Utilizing, AI-Integrated Drug Discovery Platform
Published: Nov 07, 2019 | Tags: Takeda, Reports, Results, Ninlaro, ixazomib, P-III, TOURMALINE-MM4 Study, 1L, Treatment, Multiple Myeloma, Stem Cell Transplantation
5. ?Sierra Oncology Amends its Asset Purchase Agreement with Gilead for Momelotinib Signed in 2018
Published: Nov 07, 2019 | Tags: Sierra Oncology, Amends, Asset Purchase Agreement, Gilead, Momelotinib, Signed, 2018
Published: Nov 07, 2019 | Tags: AstraZeneca, Reports, Results, Roxadustat, P-III, OLYMPUS, ROCKIES, Studies, Chronic Kidney Disease, Anaemia
7. ?? Teva and Celltrion Reports the Availability of Truxima (biosimilar, Rituxan) in the US
Published: Nov 07, 2019 | Tags: Teva, Celltrion, Reports, Availability, Truxima, biosimilar, Rituxan, US
Published: Nov 07, 2019 | Tags: Bio Thera, QLETLI, biosimilar, adalimumab, Receives, NMPA, Approval, Auto-Immune Diseases, China
9. AstraZeneca to Invest $1B for the Transformation of Healthcare in China
Published: Nov 06, 2019 | Tags: AstraZeneca, Invest, $1B, Transformation, Healthcare, China
Published: Nov 07, 2019 | Tags: STADA, Signs, Exclusive, Commercialization Agreement, Alvotech, Seven, Biosimilars, Europe
11. ? Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014
Published: Nov 07, 2019 | Tags: Novo Nordisk, Signs, Exclusive, Worldwide, License Agreement, UBE Industries, UD-014
12. ?Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases
Published: Oct 24, 2019 | Tags: Novartis, Collaborates, Pliant Therapeutics, Develop, Therapies, NASH, Fibrotic Diseases
?13. ? Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda
Published: Nov 06, 2019 | Tags: Merck, Signs, Worldwide, Agreement, Promega, Develop, MSI Technology, CDx, Keytruda, pembrolizumab
Published: Nov 06, 2019 | Tags: Coherus, Signs, Exclusive, License Agreement, Bioeq, Biosimilar, Lucentis, ranibizumab, US
Published: Nov 06, 2019 | Tags: Biogen, Signs, Commercialization Agreement, Samsung Bioepis, Expand, Biosimilars Portfolio
Published: Nov 06, 2019 | Tags: Agreement, Oncolytic Virus-Based, Option To License, Regeneron, Research, Signs, Therapies, Vyriad
17. Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma Outside Japan
Published: Nov 06, 2019 | Tags: Eisai, Transfer, Royalty Rights, Royalty Pharma, Tazemetostat, Outside, Japan
Published: Nov 06, 2019 | Tags: Evotec, Collaborates, Vifor Pharma, Launch, Joint Venture, Discover, Develop, Therapies, Nephrology
Published: Nov 05, 2019 | Tags: Vela Diagnostics, Sentosa SQ HIV-1 Genotyping Assay, Receives, US FDA, DE Novo Authorization, Detection, HIV-1 Genomic Drug Resistance Mutations, DRMs
Published: Nov 05, 2019 | Tags: BioLineRx, Reports, Results, BL-8040, Combination, Keytruda, pembrolizumab, P-IIb Trial, Patients, Metastatic Pancreatic Cancer
Published: Nov 05, 2019 | Tags: Takeda, Signs, Exclusive, License, Research, Agreement, MD Anderson, CAR NK Cell, Therapies
Published: Nov 06, 2019 | Tags: BeiGene, Signs, Exclusive, Worldwide, License, Agreement, Seattle Genetics, Advance, Preclinical, Candidates, Treating, Cancer
23. ? Stryker to Acquire Wright Medical for $5.4B
Published: Nov 04, 2019 | Tags: Stryker, Acquire, Wright Medical, $5.4B
Published: Nov 04, 2019 | Tags: Henlius, Ascentage Pharma, Collaborate, Evaluate, Combination Therapy, Chronic Lymphocytic Leukemia, China
Published: Nov 04, 2019 | Tags: Sanofi, Fluzone, High-Dose Quadrivalent, Influenza Vaccine, Receives, FDA, Approval, Adults, Aged= 65yrs.
26. ? Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M
Published: Nov 05, 2019 | Tags: Takeda, Divest, Portfolio, Select OTC, Non-Core Assets, STADA, $660M
Published: Nov 05, 2019 | Tags: Sandoz, Ziextenzo, biosimilar, pegfilgrastim, Receives, US, FDA, Approval, Decrease, Incidence of Febrile Neutropenia
Published: Nov 04, 2019 | Tags: Boehringer Ingelheim, Lilly, Modernize, Alliance, Emphasis, Full, Expertise, Investment, Jardiance
Published: Nov 04, 2019 | Tags: Halozyme, Discontinue, P-III, HALO-301 Study, PEGPH20, Treatment, Metastatic Pancreatic Cancer
Published: Nov 04, 2019 | Tags: Yas Holding, Acquire, Stake, Alvotech, Signs, Exclusive, Partnership, Three, Biosimilar Candidates
Published: Nov 04, 2019 | Tags: Janssen, Collaborates, Vifor Pharma, Co-commercialize, Invokana, canagliflozin, Treat, Diabetic Kidney Disease, US
Published: Nov 04, 2019 | Tags: Sanofi, Reports, Positive Results, Toujeo, insulin glargine, 300 Units/mL, P-III, EDITION JUNIOR, Study, Children, Adolescents, Type 1 Diabetes
33. Google to Acquire Fitbit for ~$2.1B
Published: Nov 01, 2019 | Tags: Google, Acquire, Fitbit, ~2.1B
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com